PepEvolutionSS-31
Elamipretide
Mitochondria-targeting tetrapeptide — FDA-approved for Barth syndrome (2025), strong safety record, near-zero gray-market supply.
Verdict — C · Emerging / Mixed
A genuine FDA approval backed by phase-3 data in a rare disease, with a clean safety record. But the approved indication is narrow, and essentially no verified gray-market supply exists for the off-label longevity/performance use case. A C today pending broader clinical development.
Overview
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that stabilizes cardiolipin in the inner mitochondrial membrane, improving ATP synthesis and reducing oxidative stress. It received FDA approval in 2025 for Barth syndrome (a rare pediatric cardiomyopathy) following positive TAZPOWER phase-3 data. Beyond this narrow indication, it has been studied for heart failure, aging, and ischemia-reperfusion injury. Gray-market supply is extremely limited and largely unverifiable; the compound is not commercially manufactured for consumer use.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.